Dr. Phil Greenberg
Professor, Medicine, Oncology and Immunology
Dr. Phillip Greenberg has had a long-standing research career illuminating the principles that underlie T-cell recognition of viruses and cancer cells, determining why such responses often fail to eliminate the viral pathogen or cancer, and developing cellular and molecular approaches to manipulate cellular immunity to treat human viral and malignant diseases.
His current research includes studies in transgenic mice to elucidate the requirements for inducing therapeutically effective T-cell responses to self-proteins that are overexpressed in tumors, development of genetically-modified mice to better model human immune responses to facilitate the development of vaccines for HIV and cancer, genetic modification of T-cells to improve efficacy in adoptive therapy, and clinical trials for the treatment of leukemia with adoptive T-cell therapy.
Dr. Greenberg’s professional awards include the Cancer Research Institute William B. Coley Award for Distinguished Research in Tumor Immunology (2011), which he received jointly with Steven A. Rosenberg, MD, PhD, for their pioneering work in the development of adoptive immunotherapies for the treatment of cancer.
Dr. Greenberg graduated from Washington University with a degree in biology and, in 1971, received his Doctor of Medicine degree, summa cum laude, from the State University of New York, Downstate Medical Center. After completing postdoctoral training at the University of California at San Diego, he joined the Fred Hutchinson Cancer Research Center and the Division of Oncology at the University of Washington in 1976.